Comparative Pharmacology
Head-to-head clinical analysis: ASHLYNA versus NEXTSTELLIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASHLYNA versus NEXTSTELLIS.
ASHLYNA vs NEXTSTELLIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASHLYNA is a combination of ethinyl estradiol and drospirenone. The contraceptive effect is based on inhibition of ovulation and alterations in cervical mucus and endometrial receptivity. Drospirenone has antimineralocorticoid and antiandrogenic activity.
Combination oral contraceptive: estrogen (estetrol) and progestin (drospirenone) suppress gonadotropin release, inhibiting ovulation; increase cervical mucus viscosity, impeding sperm penetration; alter endometrial lining, reducing implantation likelihood.
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 placebo tablets.
One tablet orally once daily, each tablet containing drospirenone 3 mg and estetrol 14.2 mg, taken continuously without a break.
None Documented
None Documented
Terminal half-life: 12–15 hours; clinical context: supports once-daily dosing
Drospirenone: 30 hours; ethinyl estradiol: 12 hours. The long half-life allows once-daily dosing and stable serum concentrations.
Renal: ~60% unchanged; fecal: ~30% (metabolites); biliary: ~10%
Urine (60%) and feces (35%); drospirenone and metabolites, with enterohepatic recirculation.
Category C
Category C
Contraceptive
Contraceptive